期刊文献+

人肺腺癌A549及A549/DDP细胞株差异蛋白质组学分析 被引量:2

Comparative Proteoics Analysis of Human Lung Adenocarcinoma Cell A549 and A549/DDP
下载PDF
导出
摘要 目的比较人肺腺癌细胞株A549和耐顺铂株A549/DDP细胞的蛋白表达谱,筛选肺癌耐药相关蛋白,为阐明肿瘤细胞的耐药提供新线索。方法对两种细胞株进行比较蛋白质组学研究,利用双向凝胶电泳技术(2-DE)分离细胞总蛋白,经图像分析软件分析、基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)鉴定差异蛋白质点,并用免疫细胞化学(ICC)对部分差异蛋白进行验证。结果获得分辨率高、重复性好的A549、A549/DDP总蛋白图谱,初步筛选出差异蛋白质点,经质谱分析及数据库检索,鉴定出13种差异表达蛋白质,这些蛋白与细胞代谢、结构、解毒和DAN修复、以及信号转导等相关。结论 A549、A549/DDP细胞株存在差异表达蛋白质点,提示这些蛋白可能与A549细胞耐顺铂相关,为研究肺癌耐药提供依据。 Objective To screen drug-resistance related proteins through analysis of comparative differential proteins expression in human lung adenocarcinoma cell lines A549 and A549/DDP.Methods Comparative two-dimensional electrophoresis (2-DE) technology was performed to separate the total protein of the two cell lines. Differential proteins between A549 and A549/DDP cell lines were identified by Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). Furthermore,essential proteins were confirmed by ICC (Immunocytochemistry).Results The well-resolved, reproducible 2-DE patterns of A549 and A549/DDP were established. Thirteen differential proteins were identified by peptide mass fingerprinting (PMF). These proteins were related with cellular metabolic, structure, detoxification or repair of DNA damage and signal transduction.Conclusion There were differentially expressed proteins in A549/DDP cells, which might related with DDP resistance. The study might provide information for drug resistence study.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2010年第6期621-625,共5页 Cancer Research on Prevention and Treatment
基金 湖南省科技厅基金资助项目(2007FJ4159)
关键词 肺腺癌细胞株 耐药 蛋白质组学 双向凝胶电泳 质谱 Human lung adenocarcinoma cell lines Drug-resistance Proteome 2-DE MALDI-TOF-MS
  • 相关文献

参考文献11

二级参考文献120

共引文献268

同被引文献40

  • 1杨东叶,刘凯于,余泽华.泛素连接酶E3[J].细胞生物学杂志,2005,27(3):281-285. 被引量:16
  • 2饶敏,张淑玲,熊莉娟.蛋白酶体抑制剂MG132诱导肿瘤细胞凋亡机制的研究进展[J].医学分子生物学杂志,2005,2(4):298-301. 被引量:10
  • 3厉明,梅同华.肺癌新标志——肿瘤M2型丙酮酸激酶[J].国际检验医学杂志,2006,27(5):446-447. 被引量:9
  • 4JEMAL A,SIEGEL R,XU J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
  • 5TRIANO L R,DESHPANDE H,GETTINGER S N.Management of patients with advanced non-small cell lung cancer:current and emerging options[J].Drugs,2010,70(2):167-179.
  • 6ANDREWS J,YEH P,PAO W,et al.Molecular predictors of response to chemotherapy in non-small cell lung cancer[J].Cancer J,2011,17(2):104-113.
  • 7LAGE H.Proteomic approaches for investigation of therapy resistance in cancer[J].Proteomics ClinAppl,2009,3(8):883-911.
  • 8YAMANOY,UZAWAK,SAITOK,e t a l.Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma[J].Int J Cancer,2010,126(2):437-449.
  • 9ASHRAFIAN H,O'FLAHERTY L,ADAM J,et al.Expression profiling in progressive stages of fumarate-hydratase deficiency:the contribution of metabolic changes to tumorigenesis[J].Cancer Res,2010,70(22):9153-9165.
  • 10LE MOGUEN K,LINCET H,DESLANDES E,et al.Comparative proteomic analysis of cisplatin sensitive IGROV1ovarian carcinoma cell line and its resistant counterpart IGROV1-R10[J].Proteomics,2006,6(19):5183-5192.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部